{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T07:07:52Z","timestamp":1788937672136,"version":"build-2803163510"},"reference-count":239,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"DOI":"10.1007\/s11427-025-3311-5","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:10:18Z","timestamp":1788934218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HER2 targeted therapy resistance in breast cancer: from molecular landscape to clinical aspects"],"prefix":"10.1007","author":[{"given":"Hongyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fubing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceshi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"3311_CR1","doi-asserted-by":"crossref","unstructured":"Anon. (2022). T-DXd: new standard for HER2-low breast cancer. Cancer Discov 12, 1828.","DOI":"10.1158\/2159-8290.CD-NB2022-0043"},{"key":"3311_CR2","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1182\/blood-2013-04-497446","volume":"122","author":"M Albanesi","year":"2013","unstructured":"Albanesi, M., Mancardi, D.A., J\u00f6nsson, F., Iannascoli, B., Fiette, L., Di Santo, J.P., Lowell, C.A., and Bruhns, P. (2013). Neutrophils mediate antibody-induced antitumor effects in mice. Blood 122, 3160\u20133164.","journal-title":"Blood"},{"key":"3311_CR3","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.semcdb.2010.08.007","volume":"21","author":"DN Amin","year":"2010","unstructured":"Amin, D.N., Campbell, M.R., and Moasser, M.M. (2010). The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 21, 944\u2013950.","journal-title":"Semin Cell Dev Biol"},{"key":"3311_CR4","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1200\/JCO.2024.42.16_suppl.1009","volume":"42","author":"F Andr\u00e9","year":"2024","unstructured":"Andr\u00e9, F., Hamilton, E.P., Loi, S., Anders, C.K., Schmid, P., Stroyakovskiy, D., Villanueva, R., Pedrini, J.L., Doval, D.C., Zurawski, B., et al. (2024). DESTINY-Breast07: dose-expansion interim analysis of T-DXd monotherapy and T-DXd+pertuzumab in patients with previously untreated HER2+ mBC. J Clin Oncol 42, 1009.","journal-title":"J Clin Oncol"},{"key":"3311_CR5","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9, F., Hee Park, Y., Kim, S.B., Takano, T., Im, S.A., Borges, G., Lima, J.P., Aksoy, S., Gavila Gregori, J., De Laurentiis, M., et al. (2023). Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401, 1773\u20131785.","journal-title":"Lancet"},{"key":"3311_CR6","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","volume":"15","author":"F Andr\u00e9","year":"2014","unstructured":"Andr\u00e9, F., O\u2019Regan, R., Ozguroglu, M., Toi, M., Xu, B., Jerusalem, G., Masuda, N., Wilks, S., Arena, F., Isaacs, C., et al. (2014). Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15, 580\u2013591.","journal-title":"Lancet Oncol"},{"key":"3311_CR7","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1158\/0008-5472.CAN-10-3795","volume":"71","author":"J Arribas","year":"2011","unstructured":"Arribas, J., Baselga, J., Pedersen, K., and Parra-Palau, J.L. (2011). p95HER2 and breast cancer. Cancer Res 71, 1515\u20131519.","journal-title":"Cancer Res"},{"key":"3311_CR8","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2016.0237","volume":"2","author":"A Awada","year":"2016","unstructured":"Awada, A., Colomer, R., Inoue, K., Bondarenko, I., Badwe, R.A., Demetriou, G., Lee, S. C., Mehta, A.O., Kim, S.B., Bachelot, T., et al. (2016). Neratinib plus paclitaxel vs. trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer. JAMA Oncol 2, 1557\u20131564.","journal-title":"JAMA Oncol"},{"key":"3311_CR9","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia, A., Hu, X., Dent, R., Yonemori, K., Barrios, C.H., O\u2019Shaughnessy, J.A., Wildiers, H., Pierga, J.Y., Zhang, Q., Saura, C., et al. (2024). Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med 391, 2110\u20132122.","journal-title":"N Engl J Med"},{"key":"3311_CR10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","volume":"379","author":"J Baselga","year":"2012","unstructured":"Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., Gomez, H., Dinh, P., Fauria, K., Van Dooren, V., et al. (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379, 633\u2013640.","journal-title":"Lancet"},{"key":"3311_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrc2656","volume":"9","author":"J Baselga","year":"2009","unstructured":"Baselga, J., and Swain, S.M. (2009). Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9, 463\u2013475.","journal-title":"Nat Rev Cancer"},{"key":"3311_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck, A., Goetsch, L., Dumontet, C., and Corva\u00efa, N. (2017). Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 16, 315\u2013337.","journal-title":"Nat Rev Drug Discov"},{"key":"3311_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-011-1744-3","volume":"133","author":"B Bernasconi","year":"2012","unstructured":"Bernasconi, B., Chiaravalli, A.M., Finzi, G., Milani, K., and Tibiletti, M.G. (2012). Genetic heterogeneity in HER2 testing may influence therapy eligibility. Breast Cancer Res Treat 133, 161\u2013168.","journal-title":"Breast Cancer Res Treat"},{"key":"3311_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","volume":"12","author":"K Berns","year":"2007","unstructured":"Berns, K., Horlings, H.M., Hennessy, B.T., Madiredjo, M., Hijmans, E.M., Beelen, K., Linn, S.C., Gonzalez-Angulo, A.M., Stemke-Hale, K., Hauptmann, M., et al. (2007). A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395\u2013402.","journal-title":"Cancer Cell"},{"key":"3311_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","volume":"18","author":"EC Borden","year":"2019","unstructured":"Borden, E.C. (2019). Interferons \u03b1 and \u03b2 in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov 18, 219\u2013234.","journal-title":"Nat Rev Drug Discov"},{"key":"3311_CR16","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","volume":"3","author":"R Bose","year":"2013","unstructured":"Bose, R., Kavuri, S.M., Searleman, A.C., Shen, W., Shen, D., Koboldt, D.C., Monsey, J., Goel, N., Aronson, A.B., Li, S., et al. (2013). Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3, 224\u2013237.","journal-title":"Cancer Discov"},{"key":"3311_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1172\/JCI33154","volume":"118","author":"DM Brantley-Sieders","year":"2008","unstructured":"Brantley-Sieders, D.M., Zhuang, G., Hicks, D., Fang, W.B., Hwang, Y., Cates, J.M.M., Coffman, K., Jackson, D., Bruckheimer, E., Muraoka-Cook, R.S., et al. (2008). The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 118, 64\u201378.","journal-title":"J Clin Invest"},{"key":"3311_CR18","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/jnci\/djac227","volume":"115","author":"F Bras\u00f3-Maristany","year":"2023","unstructured":"Bras\u00f3-Maristany, F., Griguolo, G., Chic, N., Pascual, T., Par\u00e9, L., Maues, J., Galv\u00e1n, P., Dieci, M.V., Miglietta, F., Giarratano, T., et al. (2023). HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. J Natl Cancer Inst 115, 332\u2013336.","journal-title":"J Natl Cancer Inst"},{"key":"3311_CR19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/189254a0","volume":"189","author":"CH Browning","year":"1961","unstructured":"Browning, C.H. (1961). Paul Ehrlich\u2019s collected papers. Nature 189, 254\u2013255.","journal-title":"Nature"},{"key":"3311_CR20","doi-asserted-by":"publisher","first-page":"e005325","DOI":"10.1136\/jitc-2022-005325","volume":"11","author":"S Bruni","year":"2023","unstructured":"Bruni, S., Mauro, F.L., Proietti, C.J., Cordo-Russo, R.I., Rivas, M.A., Inurrigarro, G., Dupont, A., Rocha, D., Fern\u00e1ndez, E.A., Deza, E.G., et al. (2023). Blocking soluble TNFa sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression. J Immunother Cancer 11, e005325.","journal-title":"J Immunother Cancer"},{"key":"3311_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature23643","volume":"549","author":"ML Burr","year":"2017","unstructured":"Burr, M.L., Sparbier, C.E., Chan, Y.C., Williamson, J.C., Woods, K., Beavis, P.A., Lam, E.Y.N., Henderson, M.A., Bell, C.C., Stolzenburg, S., et al. (2017). CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 549, 101\u2013105.","journal-title":"Nature"},{"key":"3311_CR22","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.7150\/ijbs.94868","volume":"20","author":"R Cai","year":"2024","unstructured":"Cai, R., Chen, Q., Zhao, D., Wang, Y., Zhou, L., Zhang, K., Shan, J., Li, Z., Chen, Y., Zhang, H., et al. (2024). A high immune-related index with the suppression of cGAS-STING pathway is a key determinant to herceptin resistance in HER2+ breast cancer. Int J Biol Sci 20, 3497\u20133514.","journal-title":"Int J Biol Sci"},{"key":"3311_CR23","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1373\/49.10.1579","volume":"49","author":"WP Carney","year":"2003","unstructured":"Carney, W.P., Neumann, R., Lipton, A., Leitzel, K., Ali, S., and Price, C.P. (2003). Potential clinical utility of serum HER-2\/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 49, 1579\u20131598.","journal-title":"Clin Chem"},{"key":"3311_CR24","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","volume":"89","author":"P Carter","year":"1992","unstructured":"Carter, P., Presta, L., Gorman, C.M., Ridgway, J.B., Henner, D., Wong, W.L., Rowland, A.M., Kotts, C., Carver, M.E., and Shepard, H.M. (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89, 4285\u20134289.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3311_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13046-025-03276-z","volume":"44","author":"L Castagnoli","year":"2025","unstructured":"Castagnoli, L., Franceschini, A., Cancila, V., Dugo, M., Bigliardi, M., Chiodoni, C., Toneguzzo, P., Regondi, V., Corsetto, P.A., Pietrantonio, F., et al. (2025). CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer. J Exp Clin Cancer Res 44, 19.","journal-title":"J Exp Clin Cancer Res"},{"key":"3311_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2, 401\u2013404.","journal-title":"Cancer Discov"},{"key":"3311_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2018.05.009","volume":"430","author":"BKR Chaganty","year":"2018","unstructured":"Chaganty, B.K.R., Qiu, S., Gest, A., Lu, Y., Ivan, C., Calin, G.A., Weiner, L.M., and Fan, Z. (2018). Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN\u03b3 secretion. Cancer Lett 430, 47\u201356.","journal-title":"Cancer Lett"},{"key":"3311_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clbc.2020.09.014","volume":"21","author":"A Chan","year":"2021","unstructured":"Chan, A., Moy, B., Mansi, J., Ejlertsen, B., Holmes, F.A., Chia, S., Iwata, H., Gnant, M., Loibl, S., Barrios, C.H., et al. (2021). Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer 21, 80\u201391.e7.","journal-title":"Clin Breast Cancer"},{"key":"3311_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nbt.3391","volume":"34","author":"MT Chang","year":"2016","unstructured":"Chang, M.T., Asthana, S., Gao, S.P., Lee, B.H., Chapman, J.S., Kandoth, C., Gao, J.J., Socci, N.D., Solit, D.B., Olshen, A.B., et al. (2016). Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol 34, 155\u2013163.","journal-title":"Nat Biotechnol"},{"key":"3311_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","volume":"43","author":"Y Chen","year":"2023","unstructured":"Chen, Y., Xu, Y., Shao, Z., and Yu, K. (2023). Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun 43, 297\u2013337.","journal-title":"Cancer Commun"},{"key":"3311_CR31","doi-asserted-by":"publisher","first-page":"e2417586122","DOI":"10.1073\/pnas.2417586122","volume":"122","author":"YF Chen","year":"2025","unstructured":"Chen, Y.F., Zhang, Q.H., Zhang, Z.W., Zhou, Y.J., Liu, C.C., Shao, Z.M., and Yu, K.D. (2025). SNX10 deficiency impairs sensitivity to anti-HER2 antibody-drug conjugates via altering HER2 trafficking in HER2-positive breast cancer. Proc Natl Acad Sci USA 122, e2417586122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3311_CR32","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1158\/0008-5472.CAN-22-3558","volume":"83","author":"X Cheng","year":"2023","unstructured":"Cheng, X., Sun, Y., Highkin, M., Vemalapally, N., Jin, X., Zhou, B., Prior, J.L., Tipton, A.R., Li, S., Iliuk, A., et al. (2023). Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21-CDK4\/6-cyclin D1 axis to drive tumorigenesis and drug resistance. Cancer Res 83, 2839\u20132857.","journal-title":"Cancer Res"},{"key":"3311_CR33","doi-asserted-by":"publisher","first-page":"e202200032","DOI":"10.1002\/cmdc.202200032","volume":"17","author":"CSB Chia","year":"2022","unstructured":"Chia, C.S.B. (2022). A patent review on FDA-approved antibody-drug conjugates, their linkers and drug payloads. Chemmedchem 17, e202200032.","journal-title":"Chemmedchem"},{"key":"3311_CR34","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1200\/JCO.2007.15.8659","volume":"26","author":"S Chia","year":"2008","unstructured":"Chia, S., Norris, B., Speers, C., Cheang, M., Gilks, B., Gown, A.M., Huntsman, D., Olivotto, I.A., Nielsen, T.O., and Gelmon, K. (2008). Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26, 5697\u20135704.","journal-title":"J Clin Oncol"},{"key":"3311_CR35","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature01392","volume":"421","author":"HS Cho","year":"2003","unstructured":"Cho, H.S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney Jr, D.W., and Leahy, D.J. (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421, 756\u2013760.","journal-title":"Nature"},{"key":"3311_CR36","doi-asserted-by":"publisher","first-page":"e1421890","DOI":"10.1080\/2162402X.2017.1421890","volume":"7","author":"JH Choi","year":"2018","unstructured":"Choi, J.H., Kim, K.H., Roh, K.H., Jung, H., Lee, A., Lee, J.Y., Song, J.Y., Park, S.J., Kim, I., Lee, W.S., et al. (2018). A PI3K p110a-selective inhibitor enhances the efficacy of anti-HER2\/neu antibody therapy against breast cancer in mice. Oncoimmunology 7, e1421890.","journal-title":"Oncoimmunology"},{"key":"3311_CR37","first-page":"5123","volume":"58","author":"TA Christianson","year":"1998","unstructured":"Christianson, T.A., Doherty, J.K., Lin, Y.J., Ramsey, E.E., Holmes, R., Keenan, E.J., and Clinton, G.M. (1998). NH2-terminally truncated HER-2\/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 58, 5123\u20135129.","journal-title":"Cancer Res"},{"key":"3311_CR38","first-page":"3067","volume":"12","author":"WP Chung","year":"2022","unstructured":"Chung, W.P., Huang, W.L., Lee, C.H., Hsu, H.P., Huang, W.L., Liu, Y.Y., and Su, W.C. (2022). PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations. Am J Cancer Res 12, 3067\u20133082.","journal-title":"Am J Cancer Res"},{"key":"3311_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes, R.A., Towers, T.L., Presta, L.G., and Ravetch, J.V. (2000). Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6, 443\u2013446.","journal-title":"Nat Med"},{"key":"3311_CR40","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3390\/cancers11060737","volume":"11","author":"DM Collins","year":"2019","unstructured":"Collins, D.M., Conlon, N.T., Kannan, S., Verma, C.S., Eli, L.D., Lalani, A.S., and Crown, J. (2019). Preclinical characteristics of the irreversible Pan-HER kinase inhibitor neratinib compared with lapatinib: implications for the treatment of HER2-positive and HER2-mutated breast cancer. Cancers (Basel) 11, 737.","journal-title":"Cancers (Basel)"},{"key":"3311_CR41","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1158\/1535-7163.MCT-23-0578","volume":"23","author":"PJ Conway","year":"2024","unstructured":"Conway, P.J., Dao, J., Kovalskyy, D., Mahadevan, D., and Dray, E. (2024). Polyploidy in cancer: causal mechanisms, cancer-specific consequences, and emerging treatments. Mol Cancer Ther 23, 638\u2013647.","journal-title":"Mol Cancer Ther"},{"key":"3311_CR42","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","volume":"30","author":"J Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s, J., Hurvitz, S.A., Im, S.A., Iwata, H., Curigliano, G., Kim, S.B., Chiu, J.W.Y., Pedrini, J.L., Li, W., Yonemori, K., et al. (2024). Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med 30, 2208\u20132215.","journal-title":"Nat Med"},{"key":"3311_CR43","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s, J., Kim, S.B., Chung, W.P., Im, S.A., Park, Y.H., Hegg, R., Kim, M.H., Tseng, L. M., Petry, V., Chung, C.F., et al. (2022). Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 386, 1143\u20131154.","journal-title":"N Engl J Med"},{"key":"3311_CR44","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1126\/science.2999974","volume":"230","author":"L Coussens","year":"1985","unstructured":"Coussens, L., Yang-Feng, T.L., Liao, Y.C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T.A., Schlessinger, J., Francke, U., et al. (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230, 1132\u20131139.","journal-title":"Science"},{"key":"3311_CR45","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K.E., and Joyce, J.A. (2023). The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403.","journal-title":"Cancer Cell"},{"key":"3311_CR46","doi-asserted-by":"publisher","first-page":"12156","DOI":"10.1038\/ncomms12156","volume":"7","author":"G Deblois","year":"2016","unstructured":"Deblois, G., Smith, H.W., Tam, I.S., Gravel, S.P., Caron, M., Savage, P., Labb\u00e9, D.P., B\u00e9gin, L.R., Tremblay, M.L., Park, M., et al. (2016). ERRa mediates metabolic adaptations driving lapatinib resistance in breast cancer. Nat Commun 7, 12156.","journal-title":"Nat Commun"},{"key":"3311_CR47","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1002\/jcp.29216","volume":"235","author":"A Derakhshani","year":"2020","unstructured":"Derakhshani, A., Rezaei, Z., Safarpour, H., Sabri, M., Mir, A., Sanati, M.A., Vahidian, F., Gholamiyan Moghadam, A., Aghadoukht, A., Hajiasgharzadeh, K., et al. (2020). Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol 235, 3142\u20133156.","journal-title":"J Cell Physiol"},{"key":"3311_CR48","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago, J.Z., Modi, S., and Chandarlapaty, S. (2021). Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 18, 327\u2013344.","journal-title":"Nat Rev Clin Oncol"},{"key":"3311_CR49","first-page":"273","volume":"2","author":"JA Drebin","year":"1988","unstructured":"Drebin, J.A., Link, V.C., and Greene, M.I. (1988). Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 2, 273\u2013277.","journal-title":"Oncogene"},{"key":"3311_CR50","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0092-8674(85)80050-7","volume":"41","author":"JA Drebin","year":"1985","unstructured":"Drebin, J.A., Link, V.C., Stern, D.F., Weinberg, R.A., and Greene, M.I. (1985). Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41, 695\u2013706.","journal-title":"Cell"},{"key":"3311_CR51","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/312545a0","volume":"312","author":"JA Drebin","year":"1984","unstructured":"Drebin, J.A., Stern, D.F., Link, V.C., Weinberg, R.A., and Greene, M.I. (1984). Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 312, 545\u2013548.","journal-title":"Nature"},{"key":"3311_CR52","doi-asserted-by":"publisher","first-page":"100947","DOI":"10.1016\/j.drup.2023.100947","volume":"68","author":"R Du","year":"2023","unstructured":"Du, R., Zhang, X., Lu, X., Ma, X., Guo, X., Shi, C., Ren, X., Ma, X., He, Y., Gao, Y., et al. (2023). PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity. Drug Resist Updat 68, 100947.","journal-title":"Drug Resist Updat"},{"key":"3311_CR53","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10549-009-0592-x","volume":"122","author":"R Dua","year":"2010","unstructured":"Dua, R., Zhang, J., Nhonthachit, P., Penuel, E., Petropoulos, C., and Parry, G. (2010). EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat 122, 685\u2013697.","journal-title":"Breast Cancer Res Treat"},{"key":"3311_CR54","doi-asserted-by":"publisher","first-page":"e2309424","DOI":"10.1002\/advs.202309424","volume":"11","author":"N Duan","year":"2024","unstructured":"Duan, N., Hua, Y., Yan, X., He, Y., Zeng, T., Gong, J., Fu, Z., Li, W., and Yin, Y. (2024). Unveiling alterations of epigenetic modifications and chromatin architecture leading to lipid metabolic reprogramming during the evolutionary trastuzumab adaptation of HER2-positive breast cancer. Adv Sci 11, e2309424.","journal-title":"Adv Sci"},{"key":"3311_CR55","doi-asserted-by":"publisher","first-page":"9221","DOI":"10.1158\/0008-5472.CAN-08-1740","volume":"68","author":"PJA Eichhorn","year":"2008","unstructured":"Eichhorn, P.J.A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R.L., Valero, V., Seoane, J., Bernards, R., et al. (2008). Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR\/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68, 9221\u20139230.","journal-title":"Cancer Res"},{"key":"3311_CR56","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2353\/ajpath.2010.090885","volume":"177","author":"FJ Esteva","year":"2010","unstructured":"Esteva, F.J., Guo, H., Zhang, S., Santa-Maria, C., Stone, S., Lanchbury, J.S., Sahin, A. A., Hortobagyi, G.N., and Yu, D. (2010). PTEN, PIK3CA, p-AKT, and p-p70S6K Status. Am J Pathol 177, 1647\u20131656.","journal-title":"Am J Pathol"},{"key":"3311_CR57","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","volume":"11","author":"OM Filho","year":"2021","unstructured":"Filho, O.M., Viale, G., Stein, S., Trippa, L., Yardley, D.A., Mayer, I.A., Abramson, V.G., Arteaga, C.L., Spring, L.M., Waks, A.G., et al. (2021). Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov 11, 2474\u20132487.","journal-title":"Cancer Discov"},{"key":"3311_CR58","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/annonc\/mdi059","volume":"16","author":"MN Fornier","year":"2005","unstructured":"Fornier, M.N., Seidman, A.D., Schwartz, M.K., Ghani, F., Thiel, R., Norton, L., and Hudis, C. (2005). Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 16, 234\u2013239.","journal-title":"Ann Oncol"},{"key":"3311_CR59","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","volume":"5","author":"MC Franklin","year":"2004","unstructured":"Franklin, M.C., Carey, K.D., Vajdos, F.F., Leahy, D.J., de Vos, A.M., and Sliwkowski, M. X. (2004). Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5, 317\u2013328.","journal-title":"Cancer Cell"},{"key":"3311_CR60","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1200\/JCO.18.01511","volume":"37","author":"RA Freedman","year":"2019","unstructured":"Freedman, R.A., Gelman, R.S., Anders, C.K., Melisko, M.E., Parsons, H.A., Cropp, A. M., Silvestri, K., Cotter, C.M., Componeschi, K.P., Marte, J.M., et al. (2019). TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol 37, 1081\u20131089.","journal-title":"J Clin Oncol"},{"key":"3311_CR61","doi-asserted-by":"publisher","first-page":"21762","DOI":"10.1038\/s41598-020-78646-y","volume":"10","author":"Y Fujimoto","year":"2020","unstructured":"Fujimoto, Y., Morita, T.Y., Ohashi, A., Haeno, H., Hakozaki, Y., Fujii, M., Kashima, Y., Kobayashi, S.S., and Mukohara, T. (2020). Combination treatment with a PI3K\/Akt\/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells. Sci Rep 10, 21762.","journal-title":"Sci Rep"},{"key":"3311_CR62","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/bjc.2012.85","volume":"106","author":"A Gallardo","year":"2012","unstructured":"Gallardo, A., Lerma, E., Escuin, D., Tibau, A., Mu\u00f1oz, J., Ojeda, B., Barnadas, A., Adrover, E., S\u00e1nchez-Tejada, L., Giner, D., et al. (2012). Increased signalling of EGFR and IGF1R, and deregulation of PTEN\/PI3K\/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 106, 1367\u20131373.","journal-title":"Br J Cancer"},{"key":"3311_CR63","doi-asserted-by":"publisher","first-page":"216024","DOI":"10.1016\/j.canlet.2022.216024","volume":"554","author":"L Gandullo-S\u00e1nchez","year":"2023","unstructured":"Gandullo-S\u00e1nchez, L., and Pandiella, A. (2023). An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. Cancer Lett 554, 216024.","journal-title":"Cancer Lett"},{"key":"3311_CR64","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s11427-023-2499-2","volume":"67","author":"K Ganesan","year":"2024","unstructured":"Ganesan, K., Xu, C., Wu, J., Du, B., Liu, Q., Sui, Y., Song, C., Zhang, J., Tang, H., and Chen, J. (2024). Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K\/Akt\/mTOR pathway. Sci China Life Sci 67, 1849\u20131866.","journal-title":"Sci China Life Sci"},{"key":"3311_CR65","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, pl1.","journal-title":"Sci Signal"},{"key":"3311_CR66","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1073\/pnas.1016140108","volume":"108","author":"JT Garrett","year":"2011","unstructured":"Garrett, J.T., Olivares, M.G., Rinehart, C., Granja-Ingram, N.D., Sanchez, V., Chakrabarty, A., Dave, B., Cook, R.S., Pao, W., McKinely, E., et al. (2011). Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA 108, 5021\u20135026.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3311_CR67","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.2174\/0929867311320190008","volume":"20","author":"SS Gayle","year":"2013","unstructured":"Gayle, S.S., Castellino, R.C., Buss, M.C., and Nahta, R. (2013). MEK inhibition increases lapatinib sensitivity via modulation of FOXM1. Curr Med Chem 20, 2486\u20132499.","journal-title":"Curr Med Chem"},{"key":"3311_CR68","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1158\/0008-5472.CAN-23-2812","volume":"84","author":"ME Gedik","year":"2024","unstructured":"Gedik, M.E., Saatci, O., Oberholtzer, N., Uner, M., Akbulut Caliskan, O., Cetin, M., Aras, M., Ibis, K., Caliskan, B., Banoglu, E., et al. (2024). Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer. Cancer Res 84, 1475\u20131490.","journal-title":"Cancer Res"},{"key":"3311_CR69","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366, 883\u2013892.","journal-title":"N Engl J Med"},{"key":"3311_CR70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni, L., Pienkowski, T., Im, Y.H., Roman, L., Tseng, L.M., Liu, M.C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.A., et al. (2012). Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13, 25\u201332.","journal-title":"Lancet Oncol"},{"key":"3311_CR71","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1158\/1078-0432.CCR-14-2728","volume":"21","author":"M Giuliano","year":"2015","unstructured":"Giuliano, M., Hu, H., Wang, Y.C., Fu, X., Nardone, A., Herrera, S., Mao, S., Contreras, A., Gutierrez, C., Wang, T., et al. (2015). Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy. Clin Cancer Res 21, 3995\u20134003.","journal-title":"Clin Cancer Res"},{"key":"3311_CR72","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","volume":"29","author":"S Goel","year":"2016","unstructured":"Goel, S., Wang, Q., Watt, A.C., Tolaney, S.M., Dillon, D.A., Li, W., Ramm, S., Palmer, A.C., Yuzugullu, H., Varadan, V., et al. (2016). Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4\/6 inhibitors. Cancer Cell 29, 255\u2013269.","journal-title":"Cancer Cell"},{"key":"3311_CR73","doi-asserted-by":"publisher","first-page":"101807","DOI":"10.1016\/j.xcrm.2024.101807","volume":"5","author":"C Gong","year":"2024","unstructured":"Gong, C., Xia, Y., Zhu, Y., Yang, Y., Lin, Q., Liu, Q., Yang, W., Ling, L., Zhong, J., Duan, Z., et al. (2024). Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal\/HER2-low breast cancer: PILHLE-001 study. Cell Rep Med 5, 101807.","journal-title":"Cell Rep Med"},{"key":"3311_CR74","doi-asserted-by":"publisher","first-page":"19127","DOI":"10.1074\/jbc.M110.216887","volume":"286","author":"C Gong","year":"2011","unstructured":"Gong, C., Yao, Y., Wang, Y., Liu, B., Wu, W., Chen, J., Su, F., Yao, H., and Song, E. (2011). Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 286, 19127\u201319137.","journal-title":"J Biol Chem"},{"key":"3311_CR75","doi-asserted-by":"publisher","first-page":"e2322688121","DOI":"10.1073\/pnas.2322688121","volume":"121","author":"MA Goyette","year":"2024","unstructured":"Goyette, M.A., Stevens, L.E., DePinho, C.R., Seehawer, M., Nishida, J., Li, Z., Wilde, C. M., Li, R., Qiu, X., Pyke, A.L., et al. (2024). Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies. Proc Natl Acad Sci USA 121, e2322688121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3311_CR76","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","volume":"16","author":"D Graus-Porta","year":"1997","unstructured":"Graus-Porta, D. (1997). ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16, 1647\u20131655.","journal-title":"EMBO J"},{"key":"3311_CR77","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1158\/1078-0432.CCR-20-1731","volume":"26","author":"V Guarneri","year":"2020","unstructured":"Guarneri, V., Dieci, M.V., Bisagni, G., Brandes, A.A., Frassoldati, A., Cavanna, L., Musolino, A., Giotta, F., Rimanti, A., Garrone, O., et al. (2020). P1K3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype. Clin Cancer Res 26, 5843\u20135851.","journal-title":"Clin Cancer Res"},{"key":"3311_CR78","doi-asserted-by":"publisher","first-page":"101792","DOI":"10.1016\/j.xcrm.2024.101792","volume":"5","author":"A Gupta","year":"2024","unstructured":"Gupta, A., Michelini, F., Shao, H., Yeh, C., Drago, J.Z., Liu, D., Rosiek, E., Romin, Y., Ghafourian, N., Thyparambil, S., et al. (2024). EGFR-directed antibodies promote HER2 ADC internalization and efficacy. Cell Rep Med 5, 101792.","journal-title":"Cell Rep Med"},{"key":"3311_CR79","doi-asserted-by":"publisher","first-page":"150142","DOI":"10.1016\/j.bbrc.2024.150142","volume":"720","author":"SK Gurung","year":"2024","unstructured":"Gurung, S.K., Shevde, L.A., and Rao, S.S. (2024). Laminin I mediates resistance to lapatinib in HER2-positive brain metastatic breast cancer cells in vitro. Biochem Biophys Res Commun 720, 150142.","journal-title":"Biochem Biophys Res Commun"},{"key":"3311_CR80","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.ccell.2021.06.001","volume":"39","author":"AB Hanker","year":"2021","unstructured":"Hanker, A.B., Brown, B.P., Meiler, J., Marin, A., Jayanthan, H.S., Ye, D., Lin, C.C., Akamatsu, H., Lee, K.M., Chatterjee, S., et al. (2021). Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2\/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer Cell 39, 1099\u20131114.e8.","journal-title":"Cancer Cell"},{"key":"3311_CR81","doi-asserted-by":"publisher","first-page":"14372","DOI":"10.1073\/pnas.1303204110","volume":"110","author":"AB Hanker","year":"2013","unstructured":"Hanker, A.B., Pfefferle, A.D., Balko, J.M., Kuba, M.G., Young, C.D., Sanchez, V., Sutton, C.R., Cheng, H., Perou, C.M., Zhao, J.J., et al. (2013). Mutant P1K3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci USA 110, 14372\u201314377.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3311_CR82","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1524-4741.2007.00396.x","volume":"13","author":"W Hanna","year":"2007","unstructured":"Hanna, W., Nofech-Mozes, S., and Kahn, H.J. (2007). Intratumoral heterogeneity of HER2\/neu in breast cancer? A rare event. Breast J 13, 122\u2013129.","journal-title":"Breast J"},{"key":"3311_CR83","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/modpathol.2013.103","volume":"27","author":"WM Hanna","year":"2014","unstructured":"Hanna, W.M., R\u00fcschoff, J., Bilous, M., Coudry, R.A., Dowsett, M., Osamura, R.Y., Penault-Llorca, F., van de Vijver, M., and Viale, G. (2014). HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Modern Pathol 27, 4\u201318.","journal-title":"Modern Pathol"},{"key":"3311_CR84","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","volume":"37","author":"N Harbeck","year":"2026","unstructured":"Harbeck, N., Modi, S., Pusztai, L., Ohno, S., Wu, J., Kim, S.B., Yoshida, A., Fabi, A., Cao, X., Joseph, R., et al. (2026). Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Ann Oncol 37, 166\u2013179.","journal-title":"Ann Oncol"},{"key":"3311_CR85","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1158\/1078-0432.CCR-06-1304","volume":"13","author":"LN Harris","year":"2007","unstructured":"Harris, L.N., You, F., Schnitt, S.J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P.D., Come, S.E., Burstein, H.J., Lesnikoski, B.A., et al. (2007). Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13, 1198\u20131207.","journal-title":"Clin Cancer Res"},{"key":"3311_CR86","first-page":"2703","volume":"7","author":"DF Hayes","year":"2001","unstructured":"Hayes, D.F., Yamauchi, H., Broadwater, G., Cirrincione, C.T., Rodrigue, S.P., Berry, D. A., Younger, J., Panasci, L.L., Millard, F., and Henderson, I.C. (2001). Circulating HER-2\/erbB-2\/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: cancer and Leukemia Group B Study 8662. Clin Cancer Res 7, 2703\u20132711.","journal-title":"Clin Cancer Res"},{"key":"3311_CR87","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3390\/pharmaceutics16070890","volume":"16","author":"P High","year":"2024","unstructured":"High, P., Guernsey, C., Subramanian, S., Jacob, J., and Carmon, K.S. (2024). The evolving paradigm of antibody-drug conjugates targeting the ErbB\/HER family of receptor tyrosine kinases. Pharmaceutics 16, 890.","journal-title":"Pharmaceutics"},{"key":"3311_CR88","doi-asserted-by":"publisher","first-page":"8933","DOI":"10.1073\/pnas.1537685100","volume":"100","author":"T Holbro","year":"2003","unstructured":"Holbro, T., Beerli, R.R., Maurer, F., Koziczak, M., Barbas Iii, C.F., and Hynes, N.E. (2003). The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100, 8933\u20138938.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3311_CR89","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00428-021-03036-2","volume":"479","author":"R Horii","year":"2021","unstructured":"Horii, R., Nitta, H., Nojima, M., Maruyama, R., Ueno, T., Ito, Y., Ohno, S., Banks, P., Kanda, H., and Akiyama, F. (2021). Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer. Virchows Arch 479, 13\u201321.","journal-title":"Virchows Arch"},{"key":"3311_CR90","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","volume":"35","author":"JL Hsu","year":"2016","unstructured":"Hsu, J.L., and Hung, M.C. (2016). The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev 35, 575\u2013588.","journal-title":"Cancer Metastasis Rev"},{"key":"3311_CR91","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s43018-025-00969-4","volume":"6","author":"D Hu","year":"2025","unstructured":"Hu, D., Lyu, X., Li, Z., Ekambaram, P., Dongre, A., Freeman, T., Joy, M., Atkinson, J. M., Brown, D.D., Cai, Z., et al. (2025). p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy. Nat Cancer 6, 1202\u20131222.","journal-title":"Nat Cancer"},{"key":"3311_CR92","doi-asserted-by":"publisher","first-page":"RP103953","DOI":"10.7554\/eLife.103953","volume":"14","author":"Y Hua","year":"2025","unstructured":"Hua, Y., Duan, N., Sun, C., Yang, F., Tian, M., Sun, Y., Zhao, S., Gong, J., Liu, Q., Huang, X., et al. (2025). Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer. eLife 14, RP103953.","journal-title":"eLife"},{"key":"3311_CR93","first-page":"1165","volume":"9","author":"RM Hudziak","year":"1989","unstructured":"Hudziak, R.M., Lewis, G.D., Winget, M., Fendly, B.M., Shepard, H.M., and Ullrich, A. (1989). p185 HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9, 1165\u20131172.","journal-title":"Mol Cell Biol"},{"key":"3311_CR94","doi-asserted-by":"publisher","first-page":"175883591880733","DOI":"10.1177\/1758835918807339","volume":"10","author":"S Hurvitz","year":"2018","unstructured":"Hurvitz, S., Singh, R., Adams, B., Taguchi, J.A., Chan, D., Dichmann, R.A., Castrellon, A., Hu, E., Berkowitz, J., Mani, A., et al. (2018). Phase Ib\/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09). Ther Adv Med Oncol 10, 1758835918807339.","journal-title":"Ther Adv Med Oncol"},{"key":"3311_CR95","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10549-013-2689-5","volume":"141","author":"SA Hurvitz","year":"2013","unstructured":"Hurvitz, S.A., Dalenc, F., Campone, M., O\u2019Regan, R.M., Tjan-Heijnen, V.C., Gligorov, J., Llombart, A., Jhangiani, H., Mirshahidi, H.R., Tan-Chiu, E., et al. (2013). A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat 141, 437\u2013446.","journal-title":"Breast Cancer Res Treat"},{"key":"3311_CR96","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz, S.A., Hegg, R., Chung, W.P., Im, S.A., Jacot, W., Ganju, V., Chiu, J.W.Y., Xu, B., Hamilton, E., Madhusudan, S., et al. (2023). Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401, 105\u2013117.","journal-title":"Lancet"},{"key":"3311_CR97","doi-asserted-by":"publisher","first-page":"102924","DOI":"10.1016\/j.esmoop.2024.102924","volume":"9","author":"SA Hurvitz","year":"2024","unstructured":"Hurvitz, S.A., Kim, S.B., Chung, W.P., Im, S.A., Park, Y.H., Hegg, R., Kim, M.H., Tseng, L.M., Petry, V., Chung, C.F., et al. (2024). Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial. ESMO Open 9, 102924.","journal-title":"ESMO Open"},{"key":"3311_CR98","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature25475","volume":"554","author":"DM Hyman","year":"2018","unstructured":"Hyman, D.M., Piha-Paul, S.A., Won, H., Rodon, J., Saura, C., Shapiro, G.I., Juric, D., Quinn, D.I., Moreno, V., Doger, B., et al. (2018). HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554, 189\u2013194.","journal-title":"Nature"},{"key":"3311_CR99","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CE.S217848","volume":"14","author":"K Ishii","year":"2019","unstructured":"Ishii, K., Morii, N., and Yamashiro, H. (2019). Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy. Core Evid 14, 51\u201370.","journal-title":"Core Evid"},{"key":"3311_CR100","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","volume":"17","author":"TN Iwata","year":"2018","unstructured":"Iwata, T.N., Ishii, C., Ishida, S., Ogitani, Y., Wada, T., and Agatsuma, T. (2018). A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol Cancer Ther 17, 1494\u20131503.","journal-title":"Mol Cancer Ther"},{"key":"3311_CR101","doi-asserted-by":"publisher","first-page":"RF02","DOI":"10.1158\/1538-7445.SABCS23-RF02-03","volume":"84","author":"K Jhaveri","year":"2024","unstructured":"Jhaveri, K., Andr\u00e9, F., Hamilton, E., Schmid, P., Anders, C., Testa, L., Ganshina, I., Lu, Y.S., Im, S.A., and Young, R. (2024). Abstract RF02-03: trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced\/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08). Cancer Res 84, RF02\u201303\u2013RF02\u201303.","journal-title":"Cancer Res"},{"key":"3311_CR102","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","volume":"27","author":"S Johnston","year":"2009","unstructured":"Johnston, S., Pippen Jr, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M.J., et al. (2009). Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27, 5538\u20135546.","journal-title":"J Clin Oncol"},{"key":"3311_CR103","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","volume":"15","author":"TT Junttila","year":"2009","unstructured":"Junttila, T.T., Akita, R.W., Parsons, K., Fields, C., Lewis Phillips, G.D., Friedman, L.S., Sampath, D., and Sliwkowski, M.X. (2009). Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15, 429\u2013440.","journal-title":"Cancer Cell"},{"key":"3311_CR104","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","volume":"128","author":"TT Junttila","year":"2011","unstructured":"Junttila, T.T., Li, G., Parsons, K., Phillips, G.L., and Sliwkowski, M.X. (2011). Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128, 347\u2013356.","journal-title":"Breast Cancer Res Treat"},{"key":"3311_CR105","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.1158\/0008-5472.CAN-09-3704","volume":"70","author":"TT Junttila","year":"2010","unstructured":"Junttila, T.T., Parsons, K., Olsson, C., Lu, Y., Xin, Y., Theriault, J., Crocker, L., Pabonan, O., Baginski, T., Meng, G., et al. (2010). Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 70, 4481\u20134489.","journal-title":"Cancer Res"},{"key":"3311_CR106","doi-asserted-by":"publisher","first-page":"e26760","DOI":"10.1371\/journal.pone.0026760","volume":"6","author":"RK Kancha","year":"2011","unstructured":"Kancha, R.K., von Bubnoff, N., Bartosch, N., Peschel, C., Engh, R.A., Duyster, J., and Ouchi, T. (2011). Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS One 6, e26760.","journal-title":"PLoS One"},{"key":"3311_CR107","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/annonc\/mdp304","volume":"21","author":"Y Kataoka","year":"2010","unstructured":"Kataoka, Y., Mukohara, T., Shimada, H., Saijo, N., Hirai, M., and Minami, H. (2010). Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 21, 255\u2013262.","journal-title":"Ann Oncol"},{"key":"3311_CR108","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1091\/mbc.e04-07-0567","volume":"16","author":"H Khoury","year":"2005","unstructured":"Khoury, H., Naujokas, M.A., Zuo, D., Sangwan, V., Frigault, M.M., Petkiewicz, S., Dankort, D.L., Muller, W.J., and Park, M. (2005). HGF converts ErbB2\/neu epithelial morphogenesis to cell invasion. Mol Biol Cell 16, 550\u2013561.","journal-title":"Mol Biol Cell"},{"key":"3311_CR109","first-page":"25","volume":"77","author":"LN Klapper","year":"2000","unstructured":"Klapper, L.N., Kirschbaum, M.H., Sela, M., and Yarden, Y. (2000). Biochemical and clinical implications of the ErbB\/HER signaling network of growth factor receptors. Adv Cancer Res 77, 25\u201379.","journal-title":"Adv Cancer Res"},{"key":"3311_CR110","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D.C., Fulton, R.S., McLellan, M.D., Schmidt, H., Kalicki-Veizer, J., McMichael, J.F., Fulton, L.L., Dooling, D.J., Ding, L., Mardis, E.R., et al. (2012). Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370.","journal-title":"Nature"},{"key":"3311_CR111","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/PAP.0000000000000015","volume":"21","author":"U Krishnamurti","year":"2014","unstructured":"Krishnamurti, U., and Silverman, J.F. (2014). HER2 in breast cancer. Adv Anatomic Pathol 21, 100\u2013107.","journal-title":"Adv Anatomic Pathol"},{"key":"3311_CR112","doi-asserted-by":"publisher","first-page":"TPS1111","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1111","volume":"40","author":"IE Krop","year":"2022","unstructured":"Krop, I.E., Carey, L.A., Ramos, J., Chen, Y., and Hamilton, E.P. (2022). Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress). J Clin Oncol 40, TPS1111.","journal-title":"J Clin Oncol"},{"key":"3311_CR113","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","volume":"19","author":"A Kulukian","year":"2020","unstructured":"Kulukian, A., Lee, P., Taylor, J., Rosler, R., de Vries, P., Watson, D., Forero-Torres, A., and Peterson, S. (2020). Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther 19, 976\u2013987.","journal-title":"Mol Cancer Ther"},{"key":"3311_CR114","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.bbcan.2012.03.012","volume":"1826","author":"L Lam","year":"2012","unstructured":"Lam, L., McAndrew, N., Yee, M., Fu, T., Tchou, J.C., and Zhang, H. (2012). Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta Rev Cancer 1826, 199\u2013208.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3311_CR115","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","volume":"26","author":"HJ Lee","year":"2014","unstructured":"Lee, H.J., Zhuang, G., Cao, Y., Du, P., Kim, H.J., and Settleman, J. (2014). Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26, 207\u2013221.","journal-title":"Cancer Cell"},{"key":"3311_CR116","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13046-024-03143-3","volume":"43","author":"J Lee","year":"2024","unstructured":"Lee, J., Kida, K., Koh, J., Liu, H., Manyam, G.C., Gi, Y.J., Rampa, D.R., Multani, A.S., Wang, J., Jayachandran, G., et al. (2024). The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer. J Exp Clin Cancer Res 43, 236.","journal-title":"J Exp Clin Cancer Res"},{"key":"3311_CR117","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-08-0380","volume":"68","author":"ST Lee-Hoeflich","year":"2008","unstructured":"Lee-Hoeflich, S.T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, K.P., Sliwkowski, M.X., and Stern, H.M. (2008). A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68, 5878\u20135887.","journal-title":"Cancer Res"},{"key":"3311_CR118","doi-asserted-by":"publisher","first-page":"8317","DOI":"10.18632\/oncotarget.2135","volume":"5","author":"G Li","year":"2014","unstructured":"Li, G., Zhao, L., Li, W., Fan, K., Qian, W., Hou, S., Wang, H., Dai, J., Wei, H., and Guo, Y. (2014). Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget 5, 8317\u20138329.","journal-title":"Oncotarget"},{"key":"3311_CR119","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41467-018-03537-w","volume":"9","author":"H Li","year":"2018","unstructured":"Li, H., Liu, J., Chen, J., Wang, H., Yang, L., Chen, F., Fan, S., Wang, J., Shao, B., Yin, D., et al. (2018). A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nat Commun 9, 1614.","journal-title":"Nat Commun"},{"key":"3311_CR120","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12943-020-01259-6","volume":"19","author":"J Li","year":"2020","unstructured":"Li, J., Ma, M., Yang, X., Zhang, M., Luo, J., Zhou, H., Huang, N., Xiao, F., Lai, B., Lv, W., et al. (2020). Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab. Mol Cancer 19, 142.","journal-title":"Mol Cancer"},{"key":"3311_CR121","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.annonc.2025.02.011","volume":"36","author":"JJ Li","year":"2025","unstructured":"Li, J.J., Wang, Z.H., Chen, L., Zhang, W.J., Ma, L.X.X., Wu, J., Liu, G.Y., Hou, Y.F., Yu, K.D., Di, G.H., et al. (2025). Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial. Ann Oncol 36, 651\u2013659.","journal-title":"Ann Oncol"},{"key":"3311_CR122","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1158\/0008-5472.CAN-23-4066","volume":"84","author":"YW Li","year":"2024","unstructured":"Li, Y.W., Dai, L.J., Wu, X.R., Zhao, S., Xu, Y.Z., Jin, X., Xiao, Y., Wang, Y., Lin, C.J., Zhou, Y.F., et al. (2024). Molecular characterization and classification of HER2-positive breast cancer inform tailored therapeutic strategies. Cancer Res 84, 3669\u20133683.","journal-title":"Cancer Res"},{"key":"3311_CR123","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1093\/oncolo\/oyad228","volume":"29","author":"X Liang","year":"2024","unstructured":"Liang, X., Gui, X., Yan, Y., Di, L., Liu, X., Li, H., and Song, G. (2024). Long-term outcome analysis of pyrotinib in patients with HER2-positive metastatic breast cancer and brain metastasis: a real-world study. Oncologist 29, e198\u2013e205.","journal-title":"Oncologist"},{"key":"3311_CR124","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","volume":"9","author":"NU Lin","year":"2023","unstructured":"Lin, N.U., Murthy, R.K., Abramson, V., Anders, C., Bachelot, T., Bedard, P.L., Borges, V., Cameron, D., Carey, L.A., Chien, A.J., et al. (2023). Tucatinib vs. placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases. JAMA Oncol 9, 197\u2013205.","journal-title":"JAMA Oncol"},{"key":"3311_CR125","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1158\/1078-0432.CCR-06-2478","volume":"13","author":"NU Lin","year":"2007","unstructured":"Lin, N.U., and Winer, E.P. (2007). Brain metastases: the HER2 paradigm. Clin Cancer Res 13, 1648\u20131655.","journal-title":"Clin Cancer Res"},{"key":"3311_CR126","first-page":"639","volume":"6","author":"YZ Lin","year":"1991","unstructured":"Lin, Y.Z., and Clinton, G.M. (1991). A soluble protein related to the HER-2 protooncogene product is released from human breast carcinoma cells. Oncogene 6, 639\u2013643.","journal-title":"Oncogene"},{"key":"3311_CR127","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-025-02181-3","volume":"10","author":"C Liu","year":"2025","unstructured":"Liu, C., Sun, L., Niu, N., Hou, P., Chen, G., Wang, H., Zhang, Z., Jiang, X., Xu, Q., Zhao, Y., et al. (2025). Molecular classification of hormone receptor-positive\/HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies. Sig Transduct Target Ther 10, 97.","journal-title":"Sig Transduct Target Ther"},{"key":"3311_CR128","doi-asserted-by":"publisher","first-page":"657","DOI":"10.4161\/cbt.5.6.2708","volume":"5","author":"PCC Liu","year":"2006","unstructured":"Liu, P.C.C., Liu, X., Li, Y., Covington, M., Wynn, R., Huber, R., Hillman, M., Yang, G., Ellis, D., Marando, C., et al. (2006). Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther 5, 657\u2013664.","journal-title":"Cancer Biol Ther"},{"key":"3311_CR129","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","volume":"18","author":"A Llombart-Cussac","year":"2017","unstructured":"Llombart-Cussac, A., Cort\u00e9s, J., Par\u00e9, L., Galvan, P., Bermejo, B., Martinez, N., Vidal, M., Pernas, S., Lopez, R., Mu\u00f1oz, M., et al. (2017). HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol 18, 545\u2013554.","journal-title":"Lancet Oncol"},{"key":"3311_CR130","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/annonc\/mdw197","volume":"27","author":"S Loibl","year":"2016","unstructured":"Loibl, S., Majewski, I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., Denkert, C., Schem, C., Sotiriou, C., Loi, S., et al. (2016). PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol 27, 1519\u20131525.","journal-title":"Ann Oncol"},{"key":"3311_CR131","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1056\/NEJMoa2514661","volume":"394","author":"S Loibl","year":"2026","unstructured":"Loibl, S., Park, Y.H., Shao, Z., Huang, C.S., Barrios, C., Abraham, J., Prat, A., Niikura, N., Im, S.A., and Li, W. (2026). Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N Engl J Med 394, 1352.","journal-title":"N Engl J Med"},{"key":"3311_CR132","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1158\/1078-0432.CCR-11-0762","volume":"17","author":"PM LoRusso","year":"2011","unstructured":"LoRusso, P.M., Weiss, D., Guardino, E., Girish, S., and Sliwkowski, M.X. (2011). Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 17, 6437\u20136447.","journal-title":"Clin Cancer Res"},{"key":"3311_CR133","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.1158\/1078-0432.CCR-06-2837","volume":"13","author":"CH Lu","year":"2007","unstructured":"Lu, C.H., Wyszomierski, S.L., Tseng, L.M., Sun, M.H., Lan, K.H., Neal, C.L., Mills, G.B., Hortobagyi, G.N., Esteva, F.J., and Yu, D. (2007). Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 13, 5883\u20135888.","journal-title":"Clin Cancer Res"},{"key":"3311_CR134","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","volume":"93","author":"Y Lu","year":"2001","unstructured":"Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., and Pollak, M. (2001). Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). JNCI J Natl Cancer Inst 93, 1852\u20131857.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"3311_CR135","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2025.03.017","volume":"43","author":"D Ma","year":"2025","unstructured":"Ma, D., Dai, L.J., Wu, X.R., Liu, C.L., Zhao, S., Zhang, H., Chen, L., Xiao, Y., Li, M., Zhao, Y.Z., et al. (2025). Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer. Cancer Cell 43, 1061\u20131075.e7.","journal-title":"Cancer Cell"},{"key":"3311_CR136","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.molonc.2013.02.011","volume":"7","author":"S Mamidi","year":"2013","unstructured":"Mamidi, S., Cinci, M., Hasmann, M., Fehring, V., and Kirschfink, M. (2013). Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. Mol Oncol 7, 580\u2013594.","journal-title":"Mol Oncol"},{"key":"3311_CR137","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/0008-5472.CAN-23-1459","volume":"84","author":"M Marquez-Palencia","year":"2024","unstructured":"Marquez-Palencia, M., Reza Herrera, L., Parida, P.K., Ghosh, S., Kim, K., Das, N.M., Gonzalez-Ericsson, P.I., Sanders, M.E., Mobley, B.C., Diegeler, S., et al. (2024). AXL\/WRNIP1 mediates replication stress response and promotes therapy resistance and metachronous metastasis in HER2+ breast cancer. Cancer Res 84, 675\u2013687.","journal-title":"Cancer Res"},{"key":"3311_CR138","doi-asserted-by":"publisher","first-page":"e1362530","DOI":"10.1080\/2162402X.2017.1362530","volume":"6","author":"VG Martinez","year":"2017","unstructured":"Martinez, V.G., O\u2019Neill, S., Salimu, J., Breslin, S., Clayton, A., Crown, J., and O\u2019Driscoll, L. (2017). Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles. Oncoimmunology 6, e1362530.","journal-title":"Oncoimmunology"},{"key":"3311_CR139","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk, A., Janiszewska, M., and Polyak, K. (2020). Intratumor heterogeneity: the rosetta stone of therapy resistance. Cancer Cell 37, 471\u2013484.","journal-title":"Cancer Cell"},{"key":"3311_CR140","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1158\/1078-0432.CCR-16-0970","volume":"23","author":"MF Mercogliano","year":"2017","unstructured":"Mercogliano, M.F., De Martino, M., Venturutti, L., Rivas, M.A., Proietti, C.J., Inurrigarro, G., Frahm, I., Allemand, D.H., Deza, E.G., Ares, S., et al. (2017). TNF\u03b1-induced mucin 4 expression elicits trastuzumab resistance in HER2-positive breast cancer. Clin Cancer Res 23, 636\u2013648.","journal-title":"Clin Cancer Res"},{"key":"3311_CR141","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-13-0518","volume":"19","author":"O Metzger-Filho","year":"2013","unstructured":"Metzger-Filho, O., Winer, E.P., and Krop, I. (2013). Pertuzumab: optimizing HER2 blockade. Clin Cancer Res 19, 5552\u20135556.","journal-title":"Clin Cancer Res"},{"key":"3311_CR142","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature23669","volume":"549","author":"R Mezzadra","year":"2017","unstructured":"Mezzadra, R., Sun, C., Jae, L.T., Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M.E.W., Slagter, M., Rozeman, E.A., Hofland, I., et al. (2017). Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 549, 106\u2013110.","journal-title":"Nature"},{"key":"3311_CR143","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N.T., Prat, A., Chae, Y.S., et al. (2022). Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387, 9\u201320.","journal-title":"N Engl J Med"},{"key":"3311_CR144","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi, S., Saura, C., Yamashita, T., Park, Y.H., Kim, S.B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020). Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382, 610\u2013621.","journal-title":"N Engl J Med"},{"key":"3311_CR145","first-page":"4744","volume":"61","author":"MA Molina","year":"2001","unstructured":"Molina, M.A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., and Baselga, J. (2001). Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61, 4744\u20134749.","journal-title":"Cancer Res"},{"key":"3311_CR146","first-page":"347","volume":"8","author":"MA Molina","year":"2002","unstructured":"Molina, M.A., Saez, R., Ramsey, E.E., Garcia-Barchino, M.J., Rojo, F., Evans, A.J., Albanell, J., Keenan, E.J., Lluch, A., and Garcia-Conde, J. (2002). NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 8, 347\u2013353.","journal-title":"Clin Cancer Res"},{"key":"3311_CR147","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/s44321-024-00088-0","volume":"16","author":"M Momeny","year":"2024","unstructured":"Momeny, M., Tienhaara, M., Sharma, M., Chakroborty, D., Varjus, R., Takala, I., Merisaari, J., Padzik, A., Vogt, A., Paatero, I., et al. (2024). DUSP6 inhibition overcomes neuregulin\/HER3-driven therapy tolerance in HER2+ breast cancer. EMBO Mol Med 16, 1603\u20131629.","journal-title":"EMBO Mol Med"},{"key":"3311_CR148","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","volume":"31","author":"F Montemurro","year":"2020","unstructured":"Montemurro, F., Delaloge, S., Barrios, C.H., Wuerstlein, R., Anton, A., Brain, E., Hatschek, T., Kelly, C.M., Pena-Murillo, C., Yilmaz, M., et al. (2020). Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol 31, 1350\u20131358.","journal-title":"Ann Oncol"},{"key":"3311_CR149","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.2010.32.2321","volume":"29","author":"PK Morrow","year":"2011","unstructured":"Morrow, P.K., Wulf, G.M., Ensor, J., Booser, D.J., Moore, J.A., Flores, P.R., Xiong, Y., Zhang, S., Krop, I.E., Winer, E.P., et al. (2011). Phase I\/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 29, 3126\u20133132.","journal-title":"J Clin Oncol"},{"key":"3311_CR150","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele, F., Deluche, E., Lusque, A., Le Bescond, L., Filleron, T., Pradat, Y., Ducoulombier, A., Pistilli, B., Bachelot, T., Viret, F., et al. (2023). Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med 29, 2110\u20132120.","journal-title":"Nat Med"},{"key":"3311_CR151","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3389\/fimmu.2017.01544","volume":"8","author":"A Muntasell","year":"2017","unstructured":"Muntasell, A., Cabo, M., Servitja, S., Tusquets, I., Mart\u00ednez-Garc\u00eda, M., Rovira, A., Rojo, F., Albanell, J., and L\u00f3pez-Botet, M. (2017). Interplay between natural killer cells and anti-HER2 antibodies: perspectives for breast cancer immunotherapy. Front Immunol 8, 1544.","journal-title":"Front Immunol"},{"key":"3311_CR152","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy, R.K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S.A., Lin, N.U., Borges, V., Abramson, V., Anders, C., et al. (2020). Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382, 597\u2013609.","journal-title":"N Engl J Med"},{"key":"3311_CR153","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","volume":"6","author":"Y Nagata","year":"2004","unstructured":"Nagata, Y., Lan, K.H., Zhou, X., Tan, M., Esteva, F.J., Sahin, A.A., Klos, K.S., Li, P., Monia, B.P., Nguyen, N.T., et al. (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117\u2013127.","journal-title":"Cancer Cell"},{"key":"3311_CR154","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","volume":"65","author":"P Nagy","year":"2005","unstructured":"Nagy, P., Friedl\u00e4nder, E., Tanner, M., Kapanen, A.I., Carraway, K.L., Isola, J., and Jovin, T.M. (2005). Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65, 473\u2013482.","journal-title":"Cancer Res"},{"key":"3311_CR155","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1158\/0008-5472.CAN-03-3856","volume":"64","author":"R Nahta","year":"2004","unstructured":"Nahta, R., Hung, M.C., and Esteva, F.J. (2004). The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64, 2343\u20132346.","journal-title":"Cancer Res"},{"key":"3311_CR156","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-012-2067-8","volume":"135","author":"R Nahta","year":"2012","unstructured":"Nahta, R., and O\u2019Regan, R.M. (2012). Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat 135, 39\u201348.","journal-title":"Breast Cancer Res Treat"},{"key":"3311_CR157","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1158\/1535-7163.MCT-06-0423","volume":"6","author":"R Nahta","year":"2007","unstructured":"Nahta, R., Yuan, L.X.H., Du, Y., and Esteva, F.J. (2007). Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 6, 667\u2013674.","journal-title":"Mol Cancer Ther"},{"key":"3311_CR158","doi-asserted-by":"publisher","first-page":"11118","DOI":"10.1158\/0008-5472.CAN-04-3841","volume":"65","author":"R Nahta","year":"2005","unstructured":"Nahta, R., Yuan, L.X.H., Zhang, B., Kobayashi, R., and Esteva, F.J. (2005). Insulin-like growth factor-I receptor\/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65, 11118\u201311128.","journal-title":"Cancer Res"},{"key":"3311_CR159","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.3390\/cells13171452","volume":"13","author":"B Nami","year":"2024","unstructured":"Nami, B., and Wang, Z. (2024). A non-canonical p75HER2 signaling pathway underlying trastuzumab action and resistance in breast cancer. Cells 13, 1452.","journal-title":"Cells"},{"key":"3311_CR160","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1038\/s41467-024-50998-3","volume":"15","author":"I Nandi","year":"2024","unstructured":"Nandi, I., Ji, L., Smith, H.W., Avizonis, D., Papavasiliou, V., Lavoie, C., Pacis, A., Attalla, S., Sanguin-Gendreau, V., and Muller, W.J. (2024). Targeting fatty acid oxidation enhances response to HER2-targeted therapy. Nat Commun 15, 6587.","journal-title":"Nat Commun"},{"key":"3311_CR161","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","volume":"186","author":"E Nolan","year":"2023","unstructured":"Nolan, E., Lindeman, G.J., and Visvader, J.E. (2023). Deciphering breast cancer: from biology to the clinic. Cell 186, 1708\u20131728.","journal-title":"Cell"},{"key":"3311_CR162","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1158\/1535-7163.MCT-09-1171","volume":"9","author":"NA O\u2019Brien","year":"2010","unstructured":"O\u2019Brien, N.A., Browne, B.C., Chow, L., Wang, Y., Ginther, C., Arboleda, J., Duffy, M.J., Crown, J., O\u2019Donovan, N., and Slamon, D.J. (2010). Activated phosphoinositide 3-kinase\/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 9, 1489\u20131502.","journal-title":"Mol Cancer Ther"},{"key":"3311_CR163","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016a). DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 22, 5097\u20135108.","journal-title":"Clin Cancer Res"},{"key":"3311_CR164","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y., Hagihara, K., Oitate, M., Naito, H., and Agatsuma, T. (2016b). Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 107, 1039\u20131046.","journal-title":"Cancer Sci"},{"key":"3311_CR165","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1158\/1538-7445.AM2020-1962","volume":"80","author":"DJ Olson","year":"2020","unstructured":"Olson, D.J., Kulukian, A., Taylor, J.D., Zaval, M.C., Nesterova, A., Hensley, K.M., Ulrich, M.L., Stevens, N.S., and Peterson, S.R. (2020). Abstract 1962: preclinical characterization of tucatinib in HER2-amplified xenograft and CNS implanted tumors. Cancer Res 80, 1962.","journal-title":"Cancer Res"},{"key":"3311_CR166","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.ejca.2007.08.018","volume":"43","author":"Z P\u00e1lyi-Krekk","year":"2007","unstructured":"P\u00e1lyi-Krekk, Z., Barok, M., Isola, J., Tammi, M., Sz\u00f6ll\u0151si, J., and Nagy, P. (2007). Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 43, 2423\u20132433.","journal-title":"Eur J Cancer"},{"key":"3311_CR167","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ccr.2010.06.014","volume":"18","author":"SG Park","year":"2010","unstructured":"Park, S.G., Jiang, Z., Mortenson, E.D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N.K., Greene, M., et al. (2010). The therapeutic effect of anti-HER2\/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18, 160\u2013170.","journal-title":"Cancer Cell"},{"key":"3311_CR168","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker, J.S., Mullins, M., Cheang, M.C.U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27, 1160\u20131167.","journal-title":"J Clin Oncol"},{"key":"3311_CR169","doi-asserted-by":"publisher","first-page":"dju291","DOI":"10.1093\/jnci\/dju291","volume":"106","author":"JL Parra-Palau","year":"2014","unstructured":"Parra-Palau, J.L., Morancho, B., Peg, V., Escorihuela, M., Scaltriti, M., Vicario, R., Zacarias-Fluck, M., Pedersen, K., Pandiella, A., Nuciforo, P., et al. (2014). Effect of p95HER2\/611CTF on the response to trastuzumab and chemotherapy. J Natl Cancer Inst 106, dju291.","journal-title":"J Natl Cancer Inst"},{"key":"3311_CR170","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1365-2559.2007.02897.x","volume":"52","author":"SJL Payne","year":"2008","unstructured":"Payne, S.J.L., Bowen, R.L., Jones, J.L., and Wells, C.A. (2008). Predictive markers in breast cancer\u2014the present. Histopathology 52, 82\u201390.","journal-title":"Histopathology"},{"key":"3311_CR171","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","volume":"19","author":"HL Perez","year":"2014","unstructured":"Perez, H.L., Cardarelli, P.M., Deshpande, S., Gangwar, S., Schroeder, G.M., Vite, G.D., and Borzilleri, R.M. (2014). Antibody-drug conjugates: current status and future directions. Drug Discov Today 19, 869\u2013881.","journal-title":"Drug Discov Today"},{"key":"3311_CR172","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou, C.M., S\u00f8rlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J. R., Ross, D.T., Johnsen, H., Akslen, L.A., et al. (2000). Molecular portraits of human breast tumours. Nature 406, 747\u2013752.","journal-title":"Nature"},{"key":"3311_CR173","doi-asserted-by":"publisher","first-page":"6090","DOI":"10.1128\/MCB.18.10.6090","volume":"18","author":"R Pinkas-Kramarski","year":"1998","unstructured":"Pinkas-Kramarski, R., Shelly, M., Guarino, B.C., Wang, L.M., Lyass, L., Alroy, I., Alamandi, M., Kuo, A., Moyer, J.D., Lavi, S., et al. (1998). ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol 18, 6090\u20136101.","journal-title":"Mol Cell Biol"},{"key":"3311_CR174","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/S1470-2045(20)30450-2","volume":"21","author":"A Prat","year":"2020","unstructured":"Prat, A., Guarneri, V., Par\u00e9, L., Griguolo, G., Pascual, T., Dieci, M.V., Chic, N., Gonz\u00e1lez-Farr\u00e9, B., Frassoldati, A., Sanfeliu, E., et al. (2020). A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Lancet Oncol 21, 1455\u20131464.","journal-title":"Lancet Oncol"},{"key":"3311_CR175","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/ijc.10410","volume":"99","author":"SA Price-Schiavi","year":"2002","unstructured":"Price-Schiavi, S.A., Jepson, S., Li, P., Arango, M., Rudland, P.S., Yee, L., and Carraway, K.L. (2002). Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Intl J Cancer 99, 783\u2013791.","journal-title":"Intl J Cancer"},{"key":"3311_CR176","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1200\/JCO.2017.76.7863","volume":"36","author":"M Rimawi","year":"2018","unstructured":"Rimawi, M., Ferrero, J.M., de la Haba-Rodriguez, J., Poole, C., De Placido, S., Osborne, C.K., Hegg, R., Easton, V., Wohlfarth, C., and Arpino, G. (2018). First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol 36, 2826\u20132835.","journal-title":"J Clin Oncol"},{"key":"3311_CR177","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/annonc\/12.suppl_1.S3","volume":"12","author":"I Rubin","year":"2001","unstructured":"Rubin, I., and Yarden, Y. (2001). The basic biology of HER2. Ann Oncol 12, S3\u2013S8.","journal-title":"Ann Oncol"},{"key":"3311_CR178","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/1078-0432.CCR-05-1807","volume":"12","author":"R S\u00e1ez","year":"2006","unstructured":"S\u00e1ez, R., Molina, M.A., Ramsey, E.E., Rojo, F., Keenan, E.J., Albanell, J., Lluch, A., Garc\u00eda-Conde, J., Baselga, J., and Clinton, G.M. (2006). p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 12, 424\u2013431.","journal-title":"Clin Cancer Res"},{"key":"3311_CR179","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","volume":"1","author":"R Salgado","year":"2015","unstructured":"Salgado, R., Denkert, C., Campbell, C., Savas, P., Nuciforo, P., Aura, C., de Azambuja, E., Eidtmann, H., Ellis, C.E., Baselga, J., et al. (2015). Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab. JAMA Oncol 1, 448\u2013454.","journal-title":"JAMA Oncol"},{"key":"3311_CR180","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","volume":"35","author":"C Saura","year":"2024","unstructured":"Saura, C., Modi, S., Krop, I., Park, Y.H., Kim, S.B., Tamura, K., Iwata, H., Tsurutani, J., Sohn, J., Mathias, E., et al. (2024). Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol 35, 302\u2013307.","journal-title":"Ann Oncol"},{"key":"3311_CR181","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jnci\/djk134","volume":"99","author":"M Scaltriti","year":"2007","unstructured":"Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., et al. (2007). Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. JNCI J Natl Cancer Inst 99, 628\u2013638.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"3311_CR182","doi-asserted-by":"publisher","first-page":"1010092","DOI":"10.3389\/fendo.2022.1010092","volume":"13","author":"J Scerri","year":"2022","unstructured":"Scerri, J., Scerri, C., Sch\u00e4fer-Ruoff, F., Fink, S., Templin, M., and Grech, G. (2022). PKC-mediated phosphorylation and activation of the MEK\/ERK pathway as a mechanism of acquired trastuzumab resistance in HER2-positive breast cancer. Front Endocrinol 13, 1010092.","journal-title":"Front Endocrinol"},{"key":"3311_CR183","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/312513a0","volume":"312","author":"AL Schechter","year":"1984","unstructured":"Schechter, A.L., Stern, D.F., Vaidyanathan, L., Decker, S.J., Drebin, J.A., Greene, M.I., and Weinberg, R.A. (1984). The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312, 513\u2013516.","journal-title":"Nature"},{"key":"3311_CR184","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ctrv.2016.03.012","volume":"46","author":"F Schettini","year":"2016","unstructured":"Schettini, F., Buono, G., Cardalesi, C., Desideri, I., De Placido, S., and Del Mastro, L. (2016). hormone receptor\/human epidermal growth factor receptor 2-positive breast cancer: where we are now and where we are going. Cancer Treat Rev 46, 20\u201326.","journal-title":"Cancer Treat Rev"},{"key":"3311_CR185","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","volume":"69","author":"W Scheuer","year":"2009","unstructured":"Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., and Hasmann, M. (2009). Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69, 9330\u20139336.","journal-title":"Cancer Res"},{"key":"3311_CR186","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","volume":"7","author":"I Schlam","year":"2021","unstructured":"Schlam, I., and Swain, S.M. (2021). HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. npj Breast Cancer 7, 56.","journal-title":"npj Breast Cancer"},{"key":"3311_CR187","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.3390\/cancers14163996","volume":"14","author":"I Schlam","year":"2022","unstructured":"Schlam, I., Tarantino, P., and Tolaney, S.M. (2022). Overcoming resistance to HER2-directed therapies in breast cancer. Cancers 14, 3996.","journal-title":"Cancers"},{"key":"3311_CR188","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clbc.2014.07.008","volume":"15","author":"M Seiler","year":"2015","unstructured":"Seiler, M., Ray-Coquard, I., Melichar, B., Yardley, D.A., Wang, R.X., Dodion, P.F., and Lee, M.A. (2015). Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer. Clin Breast Cancer 15, 60\u201365.","journal-title":"Clin Breast Cancer"},{"key":"3311_CR189","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nbt.2289","volume":"30","author":"PD Senter","year":"2012","unstructured":"Senter, P.D., and Sievers, E.L. (2012). The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30, 631\u2013637.","journal-title":"Nat Biotechnol"},{"key":"3311_CR190","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/modpathol.2012.36","volume":"25","author":"H Seol","year":"2012","unstructured":"Seol, H., Lee, H.J., Choi, Y., Lee, H.E., Kim, Y.J., Kim, J.H., Kang, E., Kim, S.W., and Park, S.Y. (2012). Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Modern Pathol 25, 938\u2013948.","journal-title":"Modern Pathol"},{"key":"3311_CR191","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1158\/0008-5472.CAN-07-5962","volume":"68","author":"DL Shattuck","year":"2008","unstructured":"Shattuck, D.L., Miller, J.K., Carraway Iii, K.L., and Sweeney, C. (2008). Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68, 1471\u20131477.","journal-title":"Cancer Res"},{"key":"3311_CR192","doi-asserted-by":"publisher","first-page":"5714","DOI":"10.1073\/pnas.76.11.5714","volume":"76","author":"C Shih","year":"1979","unstructured":"Shih, C., Shilo, B.Z., Goldfarb, M.P., Dannenberg, A., and Weinberg, R.A. (1979). Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc Natl Acad Sci USA 76, 5714\u20135718.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3311_CR193","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235, 177\u2013182.","journal-title":"Science"},{"key":"3311_CR194","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344, 783\u2013792.","journal-title":"N Engl J Med"},{"key":"3311_CR195","doi-asserted-by":"publisher","first-page":"7142","DOI":"10.1073\/pnas.1016569108","volume":"108","author":"J Stagg","year":"2011","unstructured":"Stagg, J., Loi, S., Divisekera, U., Ngiow, S.F., Duret, H., Yagita, H., Teng, M.W., and Smyth, M.J. (2011). Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 108, 7142\u20137147.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3311_CR196","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","volume":"8","author":"K Strebhardt","year":"2008","unstructured":"Strebhardt, K., and Ullrich, A. (2008). Paul Ehrlich\u2019s magic bullet concept: 100 years of progress. Nat Rev Cancer 8, 473\u2013480.","journal-title":"Nat Rev Cancer"},{"key":"3311_CR197","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain, S.M., Baselga, J., Kim, S.B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.M., Schneeweiss, A., Heeson, S., et al. (2015). Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372, 724\u2013734.","journal-title":"N Engl J Med"},{"key":"3311_CR198","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain, S.M., Shastry, M., and Hamilton, E. (2023). Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov 22, 101\u2013126.","journal-title":"Nat Rev Drug Discov"},{"key":"3311_CR199","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jconrel.2023.10.007","volume":"363","author":"B Tao","year":"2023","unstructured":"Tao, B., Du, R., Zhang, X., Jia, B., Gao, Y., Zhao, Y., and Liu, Y. (2023). Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy. J Control Release 363, 692\u2013706.","journal-title":"J Control Release"},{"key":"3311_CR200","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1056\/NEJMoa2508668","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney, S.M., Jiang, Z., Zhang, Q., Barroso-Sousa, R., Park, Y.H., Rimawi, M.F., Saura, C., Schneeweiss, A., Toi, M., Chae, Y.S., et al. (2026). Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. N Engl J Med 394, 551\u2013562.","journal-title":"N Engl J Med"},{"key":"3311_CR201","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/19420862.2016.1204503","volume":"8","author":"G T\u00f3th","year":"2016","unstructured":"T\u00f3th, G., Sz\u0151\u0151r, \u00c1., Simon, L., Yarden, Y., Sz\u0151ll\u0151si, J., and Vereb, G. (2016). The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity. mAbs 8, 1361\u20131370.","journal-title":"mAbs"},{"key":"3311_CR202","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.pharmthera.2017.07.013","volume":"181","author":"PA Trail","year":"2018","unstructured":"Trail, P.A., Dubowchik, G.M., and Lowinger, T.B. (2018). Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design. Pharmacol Ther 181, 126\u2013142.","journal-title":"Pharmacol Ther"},{"key":"3311_CR203","doi-asserted-by":"publisher","first-page":"e131882","DOI":"10.1172\/jci.insight.131882","volume":"4","author":"LC Tsao","year":"2019","unstructured":"Tsao, L.C., Crosby, E.J., Trotter, T.N., Agarwal, P., Hwang, B.J., Acharya, C., Shuptrine, C.W., Wang, T., Wei, J., and Yang, X. (2019). CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. JCI Insight 4, e131882.","journal-title":"JCI Insight"},{"key":"3311_CR204","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1200\/JCO.2011.36.0107","volume":"29","author":"CH Tse","year":"2011","unstructured":"Tse, C.H., Hwang, H.C., Goldstein, L.C., Kandalaft, P.L., Wiley, J.C., Kussick, S.J., and Gown, A.M. (2011). Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J Clin Oncol 29, 4168\u20134174.","journal-title":"J Clin Oncol"},{"key":"3311_CR205","doi-asserted-by":"publisher","first-page":"611","DOI":"10.5858\/133.4.611","volume":"133","author":"GH Vance","year":"2009","unstructured":"Vance, G.H., Barry, T.S., Bloom, K.J., Fitzgibbons, P.L., Hicks, D.G., Jenkins, R.B., Persons, D.L., Tubbs, R.R., and Hammond, M.E.H. (2009). Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 133, 611\u2013612.","journal-title":"Arch Pathol Lab Med"},{"key":"3311_CR206","doi-asserted-by":"publisher","first-page":"103699","DOI":"10.1016\/j.esmoop.2024.103699","volume":"9","author":"M Vaz Batista","year":"2024","unstructured":"Vaz Batista, M., P\u00e9rez-Garc\u00eda, J.M., Cortez, P., Garrig\u00f3s, L., Fern\u00e1ndez-Abad, M., Gion, M., Mart\u00ednez-Bueno, A., Saavedra, C., Teruel, I., Fernandez-Ortega, A., et al. (2024). Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial. ESMO Open 9, 103699.","journal-title":"ESMO Open"},{"key":"3311_CR207","doi-asserted-by":"publisher","first-page":"PD8","DOI":"10.1158\/1538-7445.SABCS21-PD8-06","volume":"82","author":"J Veeraraghavan","year":"2022","unstructured":"Veeraraghavan, J., Bose, S., Mistry, R., Selenica, P., Nanda, S., Qin, L., Gazzo, A., Zhu, Y., Mancini, M.A., and Stossi, F. (2022). Abstract PD8-06: acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer. Cancer Res 82, PD8\u201306\u2013PD08\u201306.","journal-title":"Cancer Res"},{"key":"3311_CR208","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma, S., Miles, D., Gianni, L., Krop, I.E., Welslau, M., Baselga, J., Pegram, M., Oh, D. Y., Di\u00e9ras, V., Guardino, E., et al. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367, 1783\u20131791.","journal-title":"N Engl J Med"},{"key":"3311_CR209","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/0092-8674(90)90697-D","volume":"61","author":"T Wada","year":"1990","unstructured":"Wada, T., Qian, X., and Greene, M.I. (1990). Intermolecular association of the p185 protein and EGF receptor modulates EGF receptor function. Cell 61, 1339\u20131347.","journal-title":"Cell"},{"key":"3311_CR210","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/jamaoncol.2023.0181","volume":"9","author":"AG Waks","year":"2023","unstructured":"Waks, A.G., Ogayo, E.R., Par\u00e9, L., Mar\u00edn-Aguilera, M., Bras\u00f3-Maristany, F., Galv\u00e1n, P., Castillo, O., Martinez-S\u00e1ez, O., Vivancos, A., Villagrasa, P., et al. (2023). Assessment of the HER2DX assay in patients with ERBB2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab, and pertuzumab. JAMA Oncol 9, 835\u2013840.","journal-title":"JAMA Oncol"},{"key":"3311_CR211","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/1471-2407-11-248","volume":"11","author":"L Wang","year":"2011","unstructured":"Wang, L., Zhang, Q., Zhang, J., Sun, S., Guo, H., Jia, Z., Wang, B., Shao, Z., Wang, Z., and Hu, X. (2011a). PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 11, 248.","journal-title":"BMC Cancer"},{"key":"3311_CR212","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1038\/onc.2015.406","volume":"35","author":"Q Wang","year":"2016","unstructured":"Wang, Q., Liu, P., Spangle, J.M., Von, T., Roberts, T.M., Lin, N.U., Krop, I.E., Winer, E. P., and Zhao, J.J. (2016). PI3K-p110\u03b1 mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene 35, 3607\u20133612.","journal-title":"Oncogene"},{"key":"3311_CR213","doi-asserted-by":"publisher","first-page":"R121","DOI":"10.1186\/bcr3067","volume":"13","author":"YC Wang","year":"2011","unstructured":"Wang, Y.C., Morrison, G., Gillihan, R., Guo, J., Ward, R.M., Fu, X., Botero, M.F., Healy, N.A., Hilsenbeck, S.G., Phillips, G.L., et al. (2011b). Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers-role of estrogen receptor and HER2 reactivation. Breast Cancer Res 13, R121.","journal-title":"Breast Cancer Res"},{"key":"3311_CR214","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12032-024-02535-x","volume":"41","author":"Z Wang","year":"2024","unstructured":"Wang, Z., Lu, H., Zhong, Y., Feng, L., Jin, H., and Wang, X. (2024). Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer. Med Oncol 41, 305.","journal-title":"Med Oncol"},{"key":"3311_CR215","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1158\/1078-0432.CCR-19-3980","volume":"26","author":"S Wedam","year":"2020","unstructured":"Wedam, S., Fashoyin-Aje, L., Gao, X., Bloomquist, E., Tang, S., Sridhara, R., Goldberg, K.B., King-Kallimanis, B.L., Theoret, M.R., Ibrahim, A., et al. (2020). FDA approval summary: ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer. Clin Cancer Res 26, 4180\u20134185.","journal-title":"Clin Cancer Res"},{"key":"3311_CR216","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/339230a0","volume":"339","author":"DB Weiner","year":"1989","unstructured":"Weiner, D.B., Liu, J., Cohen, J.A., Williams, W.V., and Greene, M.I. (1989). A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 339, 230\u2013231.","journal-title":"Nature"},{"key":"3311_CR217","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10549-010-1030-9","volume":"123","author":"I Witzel","year":"2010","unstructured":"Witzel, I., Loibl, S., von Minckwitz, G., Mundhenke, C., Huober, J., Hanusch, C., Henschen, S., Hauschild, M., Lantzsch, T., Tesch, H., et al. (2010). Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res Treat 123, 437\u2013445.","journal-title":"Breast Cancer Res Treat"},{"key":"3311_CR218","doi-asserted-by":"publisher","first-page":"7795","DOI":"10.1073\/pnas.0602468103","volume":"103","author":"W Xia","year":"2006","unstructured":"Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., et al. (2006). A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 103, 7795\u20137800.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3311_CR219","doi-asserted-by":"publisher","first-page":"R85","DOI":"10.1186\/bcr3480","volume":"15","author":"W Xia","year":"2013","unstructured":"Xia, W., Petricoin Iii, E.F., Zhao, S., Liu, L., Osada, T., Cheng, Q., Wulfkuhle, J.D., Gwin, W.R., Yang, X., Gallagher, R.I., et al. (2013). An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Res 15, R85.","journal-title":"Breast Cancer Res"},{"key":"3311_CR220","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12943-023-01716-y","volume":"22","author":"F Xing","year":"2023","unstructured":"Xing, F., Gao, H., Chen, G., Sun, L., Sun, J., Qiao, X., Xue, J., and Liu, C. (2023). CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer. Mol Cancer 22, 6.","journal-title":"Mol Cancer"},{"key":"3311_CR221","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","volume":"22","author":"B Xu","year":"2021","unstructured":"Xu, B., Yan, M., Ma, F., Hu, X., Feng, J., Ouyang, Q., Tong, Z., Li, H., Zhang, Q., Sun, T., et al. (2021). Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22, 351\u2013360.","journal-title":"Lancet Oncol"},{"key":"3311_CR222","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-16-2191","volume":"23","author":"X Xu","year":"2017","unstructured":"Xu, X., De Angelis, C., Burke, K.A., Nardone, A., Hu, H., Qin, L., Veeraraghavan, J., Sethunath, V., Heiser, L.M., Wang, N., et al. (2017). HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2+ breast cancer. Clin Cancer Res 23, 5123\u20135134.","journal-title":"Clin Cancer Res"},{"key":"3311_CR223","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1470-2045(21)00716-6","volume":"23","author":"M Yan","year":"2022","unstructured":"Yan, M., Ouyang, Q., Sun, T., Niu, L., Yang, J., Li, L., Song, Y., Hao, C., Chen, Z., Orlandi, A., et al. (2022). Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial. Lancet Oncol 23, 353\u2013361.","journal-title":"Lancet Oncol"},{"key":"3311_CR224","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1007\/s11427-023-2585-5","volume":"67","author":"W Yan","year":"2024","unstructured":"Yan, W., Wang, X., Wang, W., Guo, Q., Huang, N., Chen, H., Liang, X.J., Han, Y., Liu, D., and Zhang, J. (2024). The p38\/MAPK pathway as a therapeutic target to prevent therapeutic escape of breast cancer stem cells. Sci China Life Sci 67, 1867\u20131880.","journal-title":"Sci China Life Sci"},{"key":"3311_CR225","doi-asserted-by":"publisher","first-page":"101078","DOI":"10.1016\/j.drup.2024.101078","volume":"74","author":"L Yang","year":"2024","unstructured":"Yang, L., Bhattacharya, A., Peterson, D., Li, Y., Liu, X., Marangoni, E., Robila, V., and Zhang, Y. (2024a). Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models. Drug Resist Updat 74, 101078.","journal-title":"Drug Resist Updat"},{"key":"3311_CR226","doi-asserted-by":"publisher","first-page":"e38221","DOI":"10.1016\/j.heliyon.2024.e38221","volume":"10","author":"L Yang","year":"2024","unstructured":"Yang, L., Chen, S., Wang, M., Peng, S., Zhao, H., Yang, P., Bao, G., and He, X. (2024b). Survival prediction and analysis of drug-resistance genes in HER2-positive breast cancer. Heliyon 10, e38221.","journal-title":"Heliyon"},{"key":"3311_CR227","doi-asserted-by":"publisher","first-page":"e164428","DOI":"10.1172\/JCI164428","volume":"133","author":"M Yang","year":"2023","unstructured":"Yang, M., Li, M., Kong, L., Huang, S., He, L., Liu, P., Mo, S., Lu, X., Lin, X., Xiao, Y., et al. (2023). Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer. J Clin Invest 133, e164428.","journal-title":"J Clin Invest"},{"key":"3311_CR228","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1001\/jamaoncol.2023.5791","volume":"10","author":"Z Yang","year":"2024","unstructured":"Yang, Z., Meng, J., Mei, X., Mo, M., Xiao, Q., Han, X., Zhang, L., Shi, W., Chen, X., Ma, J., et al. (2024c). Brain radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive advanced breast cancer and brain metastases. JAMA Oncol 10, 335\u2013341.","journal-title":"JAMA Oncol"},{"key":"3311_CR229","doi-asserted-by":"publisher","first-page":"109577","DOI":"10.1016\/j.cclet.2024.109577","volume":"35","author":"Z Yang","year":"2024","unstructured":"Yang, Z., Tong, Y., Liu, Y., Liu, Q., Ni, Z., He, Y., and Rao, Y. (2024d). Developing selective PI3K degraders to modulate both kinase and non-kinase functions. Chin Chem Lett 35, 109577.","journal-title":"Chin Chem Lett"},{"key":"3311_CR230","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1200\/JCO.23.02044","volume":"42","author":"H Yao","year":"2024","unstructured":"Yao, H., Yan, M., Tong, Z., Wu, X., Ryu, M.H., Park, J.J., Kim, J.H., Zhong, Y., Zhao, Y., Voskoboynik, M., et al. (2024). Safety, efficacy, and pharmacokinetics of SHR-A1811, a human epidermal growth factor receptor 2-directed antibody-drug conjugate, in human epidermal growth factor receptor 2-expressing or mutated advanced solid tumors: a global phase I trial. J Clin Oncol 42, 3453\u20133465.","journal-title":"J Clin Oncol"},{"key":"3311_CR231","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden, Y., and Sliwkowski, M.X. (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127\u2013137.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3311_CR232","doi-asserted-by":"publisher","first-page":"217900","DOI":"10.1016\/j.canlet.2025.217900","volume":"630","author":"N Yazdi","year":"2025","unstructured":"Yazdi, N., Pourjamal, N., Katainen, R., V\u00e4\u00e4n\u00e4nen, J., Dai, J., V\u00e4h\u00e4rautio, A., Isola, J., Kempas, M., Le Joncour, V., Laakkonen, P., et al. (2025). Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates. Cancer Lett 630, 217900.","journal-title":"Cancer Lett"},{"key":"3311_CR233","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes, A., Bartlett, N.L., Leonard, J.P., Kennedy, D.A., Lynch, C.M., Sievers, E.L., and Forero-Torres, A. (2010). Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363, 1812\u20131821.","journal-title":"N Engl J Med"},{"key":"3311_CR234","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1016\/S0021-9258(18)52354-1","volume":"266","author":"JR Zabrecky","year":"1991","unstructured":"Zabrecky, J.R., Lam, T., McKenzie, S.J., and Carney, W. (1991). The extracellular domain of p185\/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266, 1716\u20131720.","journal-title":"J Biol Chem"},{"key":"3311_CR235","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1172\/JCI32278","volume":"117","author":"H Zhang","year":"2007","unstructured":"Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., and Greene, M.I. (2007). ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117, 2051\u20132058.","journal-title":"J Clin Invest"},{"key":"3311_CR236","doi-asserted-by":"publisher","first-page":"217112","DOI":"10.1016\/j.canlet.2024.217112","volume":"598","author":"H Zhang","year":"2024","unstructured":"Zhang, H., Zhang, L., He, Y., Jiang, D., Sun, J., Luo, Q., Liang, H., Wang, T., Li, F., Tang, Y., et al. (2024). PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. Cancer Lett 598, 217112.","journal-title":"Cancer Lett"},{"key":"3311_CR237","doi-asserted-by":"publisher","first-page":"107677","DOI":"10.1016\/j.pharmthera.2020.107677","volume":"218","author":"T Zhang","year":"2023","unstructured":"Zhang, T., You, L., Xu, J., Yin, J., Qu, B., Mao, Y., Fu, B., Cao, D., Zhao, L., Feng, J., et al. (2023). Abstract LB031: SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles. Cancer Res 83, LB031. Zhang, Y. (2021). The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance. Pharmacol Ther 218, 107677.","journal-title":"Pharmacol Ther"},{"key":"3311_CR238","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1158\/0008-5472.CAN-09-1845","volume":"70","author":"G Zhuang","year":"2010","unstructured":"Zhuang, G., Brantley-Sieders, D.M., Vaught, D., Yu, J., Xie, L., Wells, S., Jackson, D., Muraoka-Cook, R., Arteaga, C., and Chen, J. (2010). Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 70, 299\u2013308.","journal-title":"Cancer Res"},{"key":"3311_CR239","doi-asserted-by":"publisher","first-page":"101051","DOI":"10.1016\/j.drup.2024.101051","volume":"73","author":"H Zou","year":"2024","unstructured":"Zou, H., Luo, J., Guo, Y., Deng, L., Zeng, L., Pan, Y., and Li, P. (2024). Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer. Drug Resist Updat 73, 101051.","journal-title":"Drug Resist Updat"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3311-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-025-3311-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3311-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T07:04:34Z","timestamp":1788937474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-025-3311-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":239,"alternative-id":["3311"],"URL":"https:\/\/doi.org\/10.1007\/s11427-025-3311-5","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of Interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}